

FDA CDER NextGen Portal DIA Conference – February 2023

Seyoum Senay

Supervisory Operations Research Office of Business Informatics (OBI) Center for Drug Evaluation and Research (CDER) US FDA







The views and opinions presented here represent those of the speaker and should not be considered to represent advice or guidance on behalf of the U.S. Food and Drug Administration.



AGENDA AND TABLE OF CONTENTS



What is CDER NextGen Portal?

Before and After NextGen Portal

What is New ?


User's Adoption





What is CDER NextGen Portal?

One stop shop for the purpose of Submission, Collaboration and Reporting. The portal enables sponsors to submit Drug Shortages Notifications and exempted human drug applications to the FDA CDER. This collaboration platform continues to reduce regulatory overhead for sponsors, academia, research institutes, and small businesses.




The FDA Digital Transformation

in action to promote safe and effective human drug review and approval

Before NextGen Portal

ADMINISTRATION

After NextGen Portal



FDA CDER NextGen Portal Products (non eCTD) for Submission, Collaboration and Reporting				
		Regulatory Submissions	Collaboration	Reporting
	Drug Shortages Notifications	\checkmark		\checkmark
	Research IND Application Builder	\checkmark	\checkmark	
	CARES Volume Act Reporting	\checkmark		\checkmark
	Alternate Submissions (Non eCTD Type III DMFs, EUA and others)	\checkmark		
	Orphan Drug	\checkmark		
	Drug Development Tools		\checkmark	
	Controlled Correspondence		\checkmark	
	Pre-ANDA & CPAM Meeting Request		\checkmark	
	Pre-Assignment Number		\checkmark	
	Waiver Exemption Exceptions Request	\checkmark		
	Program Fee			\checkmark
	Standards Recognition			\checkmark
	Extensions Requests			\checkmark
	Manufacturing Capacity			\checkmark
	Critical Care Drug Monitoring Portal			\checkmark
	Radioactive Drug Research Committee		\checkmark	
	Potential Drug Shortage		\checkmark	
	Emergency Use Potential Drug Shortage	\checkmark	\checkmark	
	Pre-Launch Activities Importation Requests		\checkmark	
	OMUFA	\checkmark	\checkmark	[]-

Application Submission Simplified

From days to minutes



User has the following Information:

Application / Submission Details


- IND Number: IND24840
- IND Serial Number: 0000

Company and Contact Details

- · Company Name: NIH
- · Company Address: Bethesda, MD
- Person Responsible: Adam Kohl

Product Details

- Drug Name: AIK12
- UNII:36209ITL9D
- Indication of Use: SCTID 404684003
- Study Details
 - NCT Number: 000032344




Two-way Real-Time Interactions (non eCTD)

Streamlining the Sponsor and FDA Reviewer collaboration



FDA CDER NextGen Portal User Adoption


The CDER NextGen Portal Team continue to make enhancements to improve user's experience





Need Support

The following support materials can help you get started on leveraging the CDER NextGen Portal






HOW DO I GAIN ACCESS TO THE NextGen PORTAL?

New Users

Sign up CDER NextGen Portal, navigate to <u>https://cdernextgenportal.fda.gov</u> and follow the signup instructions









Thank You

